ClinicalTrials.gg
CompletedNCT01089166Updated Jun 22, 2010

Study to Compare the Bioavailability of Extended Release Metformin HCl Tablet Versus Glucophage XR® Tablets in Healthy Human Volunteers Under Fasting Condition

A Phase 1 interventional study of Metformin in Type 2 Diabetes, sponsored by Torrent Pharmaceuticals Limited. Completed at 1 site in India. Open to male participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2010-06-22.

Sponsored by Torrent Pharmaceuticals Limited · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Phase 1
55 of 293
2 open now
Registered
104th of 293
by date

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is one of 55 in phase 1, and was the 104th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 45 Years · male.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Objective: To compare the bioavailability of Extended Release Metformin HCl Tablet(Test formulation, Torrent Pharmaceuticals Ltd.,India) versus Glucophage XR® Tablets ( Reference formulation, Bristol-Myers Squibb Company, USA) in Healthy Human Volunteers under fasting condition.

Study Design: An Open-Label, Randomised, 2-Period, 2-Treatment,Crossover Study under fasting condition.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must meet all of the following criteria in order to be included in the study:

    1. Sex: male.
    2. Age: 18 - 45 years.
    3. Subject with of 18-27 (inclusive both) kg/m2 with minimum of 50 kg weight.
    4. Healthy and willing to participate in the study.
    5. Subject willing to adhere to the protocol requirements and to provide written .
    6. Non-smokers or smoker who smokes less than 10 cigarettes a day.

Exclusion criteria

Exclusion Criteria:

  • The subjects will be excluded from the study based on the following criteria:

    1. abnormalities in the results of the laboratory screening evaluation.
    2. Clinically significant abnormal or Chest X-ray.
    3. Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg and diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.
    4. Pulse rate less than 50/minute or more than 100/minute.
    5. Oral temperature less than 95°F or more than 98.6°F.
    6. Respiratory rate less than 12/minute or more than 20/minute
    7. Addiction to alcohol or history of any drug abuse within the past 2 years.
    8. Recent History of kidney or liver dysfunction.
    9. History of allergy to the test drug or any drug chemically similar to the drug under investigation.
    10. Administration/ Intake of prescription or OTC medication for two weeks before the study.
    11. Patients suffering from any chronic illness such as arthritis, asthma etc.
    12. , , positive Subjects.
    13. Opioids, tetra hydrocannabinoids, amphetamine, barbiturates, benzodiazepine, Cocaine positive Subjects based on urine test.
    14. Subjects suffering from any psychiatric (acute or chronic) illness requiring medications.
    15. Administration of any products in the period 0 to 3 months before entry to the study.
    16. Intake of barbiturates or any enzyme-inducing drug in last three months.
    17. History of significant blood loss due to any reason, including blood donation in the past 12 weeks. The total blood loss in last 3 months including for this study will not exceed 350ml.
    18. History of any bleeding disorder.
    19. Existence of any surgical or medical condition, which, in the judgement of the Chief investigator and/or clinical investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug or likely to compromise the safety of Subjects.
    20. Inability to communicate or co-operate due to language problem, poor mental development or impaired cerebral function.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1

Study arms

  • Experimental
    Torrent's Metformin tablets 500 mg

    Drug: Metformin

  • Active comparator
    Glucophage XR® of Bristol- Myers Squibb Company, USA)

    Drug: Metformin

Interventions

06

Study locations

1 site
  • Torrent Research Centre
    Bhat, Gujarat 382 428, India
07

References and documents

Related links

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 22, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01089166
First posted
Mar 18, 2010
Last update
Jun 22, 2010

Study contacts

Jogesh mahajan, MBBS
principal investigator · Torrent Pharma Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion